Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement

Published:2016-06 Issue:6 Volume:29 Page:820-831
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Dahan Rony,Barnhart Bryan C.,Li Fubin,Yamniuk Aaron P.,Korman Alan J.,Ravetch Jeffrey V.

Funder

Bristol-Myers Squibb Company

Cancer Research Institute

NIH

Melanoma Research Alliance

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference40 articles.

1. Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis;Allen;Biochemistry,2009

2. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma;Bajor;Cancer Immunol. Res.,2014

3. FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses;Barnes;Immunity,2002

4. Tracking CD40 signaling during germinal center development;Basso;Blood,2004

5. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity;Bournazos;Cell,2014

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling spontaneous humoral immune responses against human cancer: a road to novel immunotherapies;Journal of Leukocyte Biology;2024-08-27

2. Clinical landscape of macrophage-reprogramming cancer immunotherapies;British Journal of Cancer;2024-06-03

3. Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab;Biochemical and Biophysical Research Communications;2024-06

4. Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation;Bioconjugate Chemistry;2024-05-24

5. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities;Signal Transduction and Targeted Therapy;2024-05-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3